RE:RE:RE:Ever get the feeling that:Perhaps more like a 'competition' of at least 3 companies - that we currently know of - since ONCY's Andrew de Guttadauro indicated in a recent investor conference call that both the pancreatic and breast cancer Phase 3 registration studies would be going to only one company.
From de Guttadauro's comments, and those of Matt Coffey, we are led to believe that the one company will be the one with the "highest bid" for ONCY - given that Coffey also recently spoke of entering into negotiations with the end result going to the highest bidder, as has happened with other biotech acquisitions. [such as with Immunomedics and others discussed on this message board]